{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-F2QK6IQD/076c5dd4-282c-4585-9e3c-98b556667ecd/PDF","dcterms:extent":"94 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-F2QK6IQD/cc419551-c5bf-49f7-9a73-9da34b81ceb1/TEXT","dcterms:extent":"20 KB"}],"edm:TimeSpan":{"@rdf:about":"1997-2025","edm:begin":{"@xml:lang":"en","#text":"1997"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-F2QK6IQD","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-S2P9OQWZ"},{"@xml:lang":"sl","#text":"Onkologija (Ljubljana)"}],"dcterms:issued":"2018","dc:creator":"Ovčariček, Tanja","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:22"},{"@xml:lang":"sl","#text":"str. 18-22"}],"dc:identifier":["ISSN:1408-1741","COBISSID_HOST:2990715","URN:URN:NBN:SI:doc-F2QK6IQD"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"dc:subject":[{"@xml:lang":"en","#text":"adverse events"},{"@xml:lang":"en","#text":"checkpoints inhibitors"},{"@xml:lang":"en","#text":"immunotherapy"},{"@xml:lang":"sl","#text":"imunoterapija"},{"@xml:lang":"sl","#text":"neželeni učinki"},{"@xml:lang":"sl","#text":"zaviralci kontrolnih točk"}],"dcterms:temporal":{"@rdf:resource":"1997-2025"},"dc:title":{"@xml:lang":"sl","#text":"Imunoterapija| Imunotherapy| new drugs, different adverse events| nova zdravila, drugačni sopojavi|"},"dc:description":{"@xml:lang":"sl","#text":"Imunoterapija je v zadnjih letih postala eden izmed pomembnih načinov sistemskega zdravljenja bolnikov z rakom. Priča smo bili različnim imunskim strategijam, med temi je tudi inhibicija kontrolnih točk. Zdravila proti CTLA-4, PD-1 in PD-L1 so protitelesa proti zaviralcem kontrolnih točk, ki lahko povišajo imunsko aktivnost proti rakavim celicam in tako ojačajo imunski odgovor proti raku. Večja uporaba teh zdravil pa je privedla do pojava posebne vrste imunsko pogojenih neželenih učinkov. Ti se najpogosteje izrazijo na koži, črevesju, žlezah z notranjim izločanjem, pljučih in mišično-skeletnem sistemu, lahko pa je prizadet kateri koli organ. Večina imunsko pogojenih neželenih učinkov je blagih do zmernih, v literaturi pa obstajajo poročila o hudih in življenje ogrožajočih. Pomembna je njihova zgodnja prepoznava in zdravljenje, kakor tudi multidisciplinaren pristop, da preprečimo resne zaplete"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-F2QK6IQD","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-F2QK6IQD"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-F2QK6IQD/076c5dd4-282c-4585-9e3c-98b556667ecd/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-F2QK6IQD/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-F2QK6IQD"}}}}